©The Author(s) 2025.
World J Clin Oncol. Oct 24, 2025; 16(10): 112097
Published online Oct 24, 2025. doi: 10.5306/wjco.v16.i10.112097
Published online Oct 24, 2025. doi: 10.5306/wjco.v16.i10.112097
Table 1 General information of the patients, n (%)
| Variable | Tumor (n = 20) |
| Sex | |
| Male | 11 (55.0) |
| Female | 9 (45.0) |
| Age (year) | 52.75 ± 6.52 |
| TNM stage | |
| Stage I | 3 (15.0) |
| Stage II | 5 (25.0) |
| Stage III | 8 (40.0) |
| Stage IV | 4 (20.0) |
| Histopathological type | |
| Squamous carcinoma | 12 (60.0) |
| Adenocarcinoma | 5 (25.0) |
| Adenosquamous carcinoma | 3 (15.0) |
- Citation: Dai Y, Liu YY, Cao N, Tian XW, Feng J, Hu ZZ, Xu JQ. Overcoming chemoresistance in non-small cell lung cancer: Insights into the influence of inflammatory factors on treatment response. World J Clin Oncol 2025; 16(10): 112097
- URL: https://www.wjgnet.com/2218-4333/full/v16/i10/112097.htm
- DOI: https://dx.doi.org/10.5306/wjco.v16.i10.112097